You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

Rare Diseases in China

Wednesday, November 13, 2013, 11:00 a.m. - 11:55a.m., Room 405

The establishment of China’s first national organization against rare diseases, China Rare Diseases Prevention & Treatment Alliance, reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of such drugs in China, and key leaders will discuss how they expect this field to develop.

Moderator:

  • Jeff Stevens, Managing Director & Partner, L.E.K. Consulting

Panelists:

  • Ko-Chung Lin, PhD, Founder & CEO, Pharmaessentia
  • Jerry Zeldis, MD, PhD, Chief Executive Officer, Celgene Global Health and Chief Medical Officer, Celgene Corporation
  • Lit-Fui Lau, PhD, General Manager, Lee's Pharmaceutical Holding Limited
Conferences and Events: 
BIO Convention in China

Company Partnerships in Vaccine Development

Tuesday, November 12, 2013, 11:00 a.m. - 11:55 a.m., Room 405

China, and its neighboring countries, represent a significant private sector opportunity for new vaccines. Chinese vaccine companies, working in partnership with other vaccine companies, are developing important medicine that addresses the specific unmet medical needs in China and other Asian markets. These collaborations bring novel vaccine technology into the Chinese research institutions while offering small and large Western vaccine companies the opportunity to bring new products to the growing Chinese private sector. Vaccines that protect against pneumococcal disease, HPV, influenza and RSV are in development or clinical trials. The panelists for this topic will discuss successful partnerships designed to solve key public health issues in China and other emerging markets as well as examine the availability of novel technologies, sustainable production capacity and innovation, and the potential impact on Chinese vaccine companies and their partners.

Moderator

  • Phyllis Arthur, Senior Director, Vaccines, Immunotherapeutics & Diagnostics Policy, BIO 

Panelists:

  • Li Shi, PhD, CEO, Shanghai Zerun Biotech
  • Jean-Denis Shu, MD, Medical Director, Sanofi Pasteur, China
  • Sean Du, PhD, Chief Operating Officer, Altravax

 

Conferences and Events: 
BIO Convention in China

Cancer Epigenetics and Emerging Therapies

Ten years after the sequencing of the human genome, the use of epigenetics in developing targeted cancer treatments is growing rapidly. This panel will discuss recent discoveries in epigenetic abnormalities and what the implications are for cancer treatment, in addition to specific emerging therapies on the forefront of this new and cutting-edge research.

Moderator:

• Bruno Osterwalder, MD, Senior Vice President, Senior Strategic Advisor Oncology,

Global Drug Development and Medical, Merck Serono

Panelists:

• Jean-Pierre Armand, MD, Senior Consultant, Institut Goustave Roussy

• Bing Zhu, PhD, Associate Investigator, National Institute of Biological Sciences, Beijing, China

Conferences and Events: 
BIO Convention in China

Introduction & Clinical, Non-Clinical and CRO Panels

Organized by Shanghai Newsummit Biopharma

Wednesday, November 13, 2013, 9:00 a.m. - 10:55 a.m., Room 403

9:00 a.m. - 9:40 a.m. China Healthcare Overview
• Chairman: Shao Ke, Chief Market Officer, Shanghai NewSummit Biopharma Group
The Development Trend and Requirements of Healthcare Service Industry in China
• Li Qing, Director, Development Center for Medical Science and Technology, Ministry of Health
An Overview of China Antibody Development Progress
• Guo Yajun, Director, National Engineering Center for Antibody Drug Research
9:40 a.m. - 10:20 a.m. Clinical Research and Market Development in China
This panel will explore the current state of international multi-center clinical trials in China as well as policy support for drugs originally developed in China. Specifically, this conversation will reference translational and evidence-based medicine supported by the “national project” and its use of third-party evaluations. Panelists will delve into the issue of post-market evaluations and their role in improving the standardization of clinical medicine. Determining international standards in China for multi-center clinical trials and how to accelerate the process of overseas R&D efforts will serve as core themes throughout the discussion.

Panelists
  • Chen Biao, Director of National Center for Clinical Trials on Neurodegenerative Diseases, Xuanwu Hospital of Capital Medical University 
  • Irenee Robi, General Manager, Dynasty Biotech Co Ltd
  • Wang Xin, Chairman, Beijing Bionovo
  • Zeng Ling, General Manager, Quintiles China
  • Kelvin Shao, Chief Marketing Officer, Shanghai NewSummit Biopharma Group
10:20 a.m. - 10:55 a.m. Current Situation of Pharmacology and Toxicology Research in China and the Trend of Internationalization
Panelists will discuss the current state of pharmacology and toxicology research in China, including the influence of internationalization. Specific themes will include: GLP regulation between CFDA and FDA, meeting the CFDA requirements, the future of development of GLP research in China, the current situation of GLP research in China, the latest progress in overseas PK, PD, and drug safety research.

Panelists
  • Huang Yangbin, Chief Technology Officer, Shanghai NewSummit Biopharma Group
  • Zuo Conglin, General Manager, Joinn Laboratories (Beijing)
  • Zheng Weiyi, General Manager, Nanjing Kangke Nuode Pharmaceutical Technology Co., Ltd
  • Wang Aipin, General Manager and Director of Drug Safety Evaluation Center, Peking Union Medical College, Chinese Academy of Medical Sciences
  • Chen Chunlin, Chairman, Shanghai Medicilon Inc

 

Conferences and Events: 
BIO Convention in China

Why Speak at BIO?

Submitted by admin on Wed, 2013-08-28 11:21

Frequently Asked Questions

Submitted by admin on Wed, 2013-08-28 11:01

2013 Confirmed Speakers

Below are the confirmed speakers who will present at the 2013 BIO Convention in China. Please check back frequently for updates. New speakers added daily.

Fireside Chats

West Moving East

Bernhard Kirschbaum, Ph.D.
Executive Vice President and Head of Global Research and Early Development
Merck Serono

Susan Herbert
Head of Global BD & Strategy
Merck Serono 

 

New Face of Traditional Medicine

Yan Xijun
Chairman of the Board
Tianjin Tasly Group

 

Scientific Focused Sessions

Cancer Epigenetics and Emerging Therapies

Bruno Osterwalder
Senior VP, Senior Strategic Advisor Oncology, Global Drug Development and Medical
Merck Serono

 

Business Focused Sessions

China Private Health Care Industry

Sheryl Jacobson
Life Sciences Practice Leader
Monitor Deloitte

 

Early Stage VC Funding in China

Leon Chen
Founder and Managing Partner
Frontline Bioventures

Jimmy Zhang
Managing Director
MSD Early Investments, Greater China, Merck & Co.

Edward Hu
CFO
WuXi AppTec

 

Case Studies: Partnering Models Between Chinese & Western Companies

Weishi Li
Partner
Covington & Burling LLP

Mike Liu
Head, Global Business Development
HengRui Pharmaceuticals
Conferences and Events: 
BIO Convention in China

Speaking Opportunities at BIO

Submitted by admin on Fri, 2013-08-09 14:25

2013 Sponsors

We would like to thank the 2013 BIO China sponsors for their support.

To learn more about branding opportunities at the upcoming BIO Convention in China, please contact Matt Lowe at mlowe@bio.org.

To view the 2013 BIO Convention in China Sponsorship Prospectus, click here.

Click here to view the 2012 BIO Convention in China Sponsors

Co-Host

   

 

BIO Double Helix Sponsors

 

 

BIO Helix Sponsors

 

Conference Sponsors

          

        

 

 

         
          

 

     

Lead Corporate Sponsors

 

Media Partners

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibition Management


 

 

Intelligence Partner


 

 

Conferences and Events: 
BIO Convention in China